The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion. Tevogen Bio is an advanced-stage specialty ...

New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced ...

New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced ...

New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the ...

Immunotherapy developer Tevogen (TVGN) plans to go public through a merger with SPAC Semper Paratus Acquisition Corp. (NASDAQ:LGST), with the deal estimating the enterprise value of the combined ...

WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Inc ("Tevogen Bio") is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus ...

Semper Paratus Acquisition Unt Stock Price History Explore Semper Paratus Acquisition Unt stock price history with detailed daily historical prices, including open, high, low, and volume data. Review ...

Semper Paratus will hold an extraordinary general meeting of its stockholders (the "Special Meeting") at which shareholders will be asked to consider and vote upon proposals to approve the Business ...